Filing Flows › Xeris Biopharma Holdings (XERS) › Q3 2026
Xeris Biopharma Holdings (XERS) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Xeris Biopharma Holdings (XERS) reported revenue of $107M for the third quarter 2026 (Q3 2026), +44% from a year earlier and +16% from the quarter before. Operating margin was 15.8%, net earnings $11.3M (10.5% of revenue).
Xeris Biopharma Holdings, Q3 2026: revenue $107M (+44% year over year), operating margin 15.8%, net earnings $11.3M, operating cash flow $35.5M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $107M | +16% | +44% |
| Operating profit | $16.9M | +227% | +151% |
| Net earnings | $11.3M | — | 18× |
| Operating cash flow | $35.5M | +329% | +92% |
What changed
Revenue was $107.2M in Q3 2026, up 44% year over year and up 16% from the previous quarter. Recorlev was the largest line at 67% of revenue. Recorlev added $34.6M year over year (up 93%), 105% of the total change. Gvoke declined 14%.
Operating profit was $16.9M, a 15.8% margin (up 6.7 points year over year). Of the extra revenue versus Q3 2025, 31% reached operating profit, above the 9% margin then. Total costs grew 33% against revenue growth of 44%. The fastest-growing cost line was Research & development (+48%). Net earnings were $11.3M, up 1718% year over year. The effective tax rate was 0.0%.
Operating cash flow was $35.5M (up 92% year over year), 314% of net earnings. Non-cash charges added back $300K of depreciation and amortization and $10.8M of share-based compensation. Working capital and other items added $13.1M.
Questions
What was Xeris Biopharma Holdings' revenue in the third quarter 2026?
Xeris Biopharma Holdings (XERS) reported revenue of $107M for the third quarter 2026 (Q3 2026), +44% from a year earlier and +16% from the quarter before.
Was Xeris Biopharma Holdings profitable in the third quarter 2026?
Operating profit was $16.9M (15.8% of revenue) and net earnings $11.3M.